Chronic urticaria may not be as innocent as we think: A rare case of acquired cutis laxa following chronic urticaria

Bostan, Ecem; Yalıcı-Armağan, Başak; Gököz, Özay

doi:10.1111/jocd.14520

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For treatment of CSU, the global survey study found that cyclosporine and systemic corticosteroids were used less during the pandemic, whereas use of antihistamines and omalizumab did not change [ 120 ]. Moreover, single-center studies have found no difference in SARS-CoV-2 positivity rate, or related pneumonia or hospitalizations for patients with CSU on omalizumab versus other treatments [ 123 , 124 ]. Of note, a retrospective chart review study found that male patients, but not female patients, had increased urticaria activity during the COVID-19 pandemic and, as omalizumab treatment rates were similar, the authors concluded that omalizumab efficacy has decreased in male patients; however, this requires further investigation [ 125 ].…”

Section: Omalizumabmentioning

confidence: 99%

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Casale,

Gimenez-Arnau,

Bernstein

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.

show abstract

Section: Omalizumabmentioning

confidence: 99%

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Casale,

Gimenez-Arnau,

Bernstein

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Acquired cutis laxa: a clinical review

Khodeir,

Ohanian,

Feghali

2024

Int J Dermatology

View full text Add to dashboard Cite

Acquired cutis laxa (ACL) is a rare, nonhereditary cutaneous disorder characterized by saggy inelastic skin. It has been associated with various inflammatory, autoimmune, and neoplastic diseases, in addition to certain infections and medication. This article reviews ACL the demographical, clinical, and histological features of ACL, focusing on all associated disorders. Additionally, this review article provides an in‐depth discussion of all the mechanisms implicated in the pathogenesis of ACL and all therapeutic options available; we also present an algorithm for the workup of patients with ACL. A systematic literature review was performed on PubMed/Medline and EMBASE databases, searching for all available articles on ACL with no limits on participant age, race, sex, nationality, or publication date. Ninety‐eight articles were included. The total number of included patients was 110, with a mean age of 36.4 years at presentation (range 0.25–78) and a M:F sex ratio of 1.24. ACL was most commonly associated with inflammatory disorders (43%) followed by neoplastic disorders (27%). In 73% of the neoplastic‐associated cases, ACL occurred on average 2.4 years before malignancy onset. ACL occurs months to years after an underlying inflammatory disorder. In 10% of the cases, ACL was associated with a particular drug, and in 2%, it was associated with specific infections. Data were derived from case reports, case series, letters to editors, observational studies, and abstracts. Limitations include the accuracy of published data, potential patient selection, and reporting bias. Dermatologists should be alert to these associations to provide adequate screening and management of patients with ACL.

show abstract

Chronic urticaria may not be as innocent as we think: A rare case of acquired cutis laxa following chronic urticaria

Cited by 2 publications

References 9 publications

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Acquired cutis laxa: a clinical review

Contact Info

Product

Resources

About